story of the week
Palbociclib Added to Letrozole Improves PFS in Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib in Combination With Letrozole Versus Letrozole Alone as First-Line Treatment of Oestrogen Receptor-Positive, HER2-Negative, Advanced Breast Cancer (PALOMA-1/TRIO-18): A Randomised Phase 2 Study
Lancet Oncol 2014 Dec 15;[EPub Ahead of Print], RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, R Patel, T Pinter, M Schmidt, Y Shparyk, AR Thummala, NL Voytko, C Fowst, X Huang, ST Kim, S Randolph, DJ SlamonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.